Connecting via Winsock to STN

```
Welcome to STN International!  Enter x:x

LOGINID:ssspta1600txm

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page for STN Seminar Schedule - N. America
 NEWS  2  OCT 04  Precision of EMBASE searching enhanced with new
                  chemical name field
 NEWS  3  OCT 06  Increase your retrieval consistency with new formats  or
                  for Taiwanese application numbers in CA/CAplus.
 NEWS  4  OCT 21  CA/CAplus kind code changes for Chinese patents
                  increase consistency, save time
 NEWS  5  OCT 22  New version of STN Viewer preserves custom
                  highlighting of terms when patent documents are
                  saved in .rtf format
 NEWS  6  OCT 28  INPADOCDB/INPAFAMDB: Enhancements to the US national
                  patent classification.
 NEWS  7  NOV 03  New format for Korean patent application numbers in
                  CA/CAplus increases consistency, saves time.
 NEWS  8  NOV 04  Selected STN databases scheduled for removal on
                  December 31, 2010
 NEWS  9  NOV 18  PROUSDR and SYNTHLINE Scheduled for Removal
                  December 31, 2010 by Request of Prous Science
 NEWS 10  NOV 22  Higher System Limits Increase the Power of STN
                  Substance-Based Searching
 NEWS 11  NOV 24  Search an additional 46,850 records with MEDLINE
                  backfile extension to 1946
 NEWS 12  DEC 14  New PNK Field Allows More Precise Crossover among STN
                  Patent Databases
 NEWS 13  DEC 18  ReaxysFile available on STN
 NEWS 14  DEC 21  CAS Learning Solutions -- a new online training experience
 NEWS 15  DEC 22  Value-Added Indexing Improves Access to World Traditional
                  Medicine Patents in CAplus

 NEWS EXPRESS FEBRUARY 15 10 CURRENT WINDOWS VERSION IS V8.4.2,
         AND CURRENT DISCOVER FILE IS DATED 07 JULY 2010.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN customer
  agreement.  This agreement limits use to scientific research.  Use
  for software development or design, implementation of commercial
  gateways, or use of CAS and STN data in the building of commercial
  products is prohibited and may result in loss of user privileges
  and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:55:49 ON 18 JAN 2011

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.46       0.46

FILE 'REGISTRY' ENTERED AT 11:56:54 ON 18 JAN 2011
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
```

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 17 JAN 2011 HIGHEST RN 1259483-08-3
DICTIONARY FILE UPDATES: 17 JAN 2011 HIGHEST RN 1259483-08-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2010.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading c:\program files\stnexp\queries\10540993 1.10.11 claims

L1   STRUCTURE UPLOADED

=> s l1
SAMPLE SEARCH INITIATED 11:57:28 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   484 TO ITERATE

100.0% PROCESSED   484 ITERATIONS   0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS: 8361 TO   10999
PROJECTED ANSWERS: 0 TO   0

L2   0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 11:57:34 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   9285 TO ITERATE

100.0% PROCESSED   9285 ITERATIONS   25 ANSWERS
SEARCH TIME: 00.00.01

L3   25 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS   SINCE FILE   TOTAL
                                                       ENTRY   SESSION
FULL ESTIMATED COST   196.86   197.32

FILE 'CAPLUS' ENTERED AT 11:57:37 ON 18 JAN 2011
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 18 Jan 2011 VOL 154 ISS 4
FILE LAST UPDATED: 17 Jan 2011 (20110117/ED)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2010

CAplus now includes complete International Patent Classification (IPC) reclassification data for the fourth quarter of 2010.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 6 L3

=> d bib abs hitstr 1-6

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2011 ACS on STN
AN 2009:208119 CAPLUS
DN 150:448241
TI Inhibitors of adenosine consuming parasites through polymer-assisted solution phase synthesis of lipophilic 5'-amido-5'-deoxyadenosine derivatives
AU Heidler, Philipp; Zohrabi-Kalantari, Vida; Kaiser, Marcel; Brun, Reto; Emmrich, Thomas; Link, Andreas
CS Institute of Pharmaceutical Chemistry, Philipps-University Marburg, Marburg, 35032, Germany
SO Bioorganic & Medicinal Chemistry (2009), 17(4), 1428-1436
CODEN: BMECEP; ISSN: 0968-0896
PB Elsevier B.V.
DT Journal
LA English
OS CASREACT 150:448241
GI



I

AB Given the more or less global spread of multidrug-resistant plasmodia, structurally diverse starting points for the development of chemotherapeutic agents for the treatment of malaria are urgently needed. Thus, a series of 20 adenosine derivs. with a large lipophilic substituent in N6-position, e.g. I, were prepared in order to evaluate their potential to inhibit the chloroquine resistant Plasmodium falciparum strain K1 in vitro. The rationale for synthesis of these structures was the high probability of interactions with multiple adenosine associated targets and the assumption that a large hydrophobic N6-(4-phenoxy)benzyl substitution should allow the mols. to diffuse across parasite membranes. Starting from readily available inosine, the new compds. were prepared as single isomers using a polymer-assisted acylation protocol enabling the straightforward isolation of the target compds. in pure form. Heterocyclic ring systems were synthesized on-bead on Kenner's safety-catch linker prior to acylation of the scaffold in solution Most of the highly pure compds. displayed anti-plasmodial activity in the low micromolar or even submicromolar concentration range.

IT 722505-26-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(polymer-assisted solution phase synthesis of lipophilic amido deoxyadenosine derivs. via nucleophilic substitution and acylation from carboxylic acids, amines and phenoxybenzyl adenosine, as inhibitors of adenosine consuming parasites)

RN 722505-26-2 CAPLUS
CN Adenosine, N-[(4-phenoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2011 ACS on STN
AN 2005:74688 CAPLUS
DN 142:336573
TI Synthesis of 9-(2-β-C-methyl-β-D-ribofuranosyl)-6-substituted purine derivatives as inhibitors of HCV RNA replication
AU Ding, Yili; Girardet, Jean-Luc; Hong, Zhi; Lai, Vicky C. H.; An, Haoyun; Koh, Yung-hyo; Shaw, Stephanie Z.; Zhong, Weidong
CS Valeant Pharmaceuticals International, Costa Mesa, CA, 92626, USA
SO Bioorganic & Medicinal Chemistry Letters (2005), 15(3), 709-713
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier B.V.
DT Journal
LA English
OS CASREACT 142:336573
AB A series of 9-(2'-β-C-methyl-β-D-ribofuranosyl)-6-substituted purine derivs. were synthesized as potential inhibitors of HCV RNA replication. Their inhibitory activities in a cell based HCV replicon assay were reported. A prodrug approach was used to further improve the potency of these compds. by increasing the intracellular levels of 5'-monophosphate metabolites. These nucleotide prodrugs showed much improved inhibitory activities of HCV RNA replication.
IT 565435-06-5P
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis of 9-(2-β-C-methyl-β-D-ribofuranosyl)-6-substituted purine deriv. as inhibitors of HCV RNA replication)
RN 565435-06-5 CAPLUS
CN Adenosine, N-[(2-ethoxyphenyl)methyl]-2'-C-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



OSC.G 23 THERE ARE 23 CAPLUS RECORDS THAT CITE THIS RECORD (23 CITINGS)
RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2011 ACS on STN
AN 2004:566634 CAPLUS
DN 141:123865
TI Substitution derivatives of N6-benzyl-adenosine, methods of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds
IN Dolezal, Karel; Popa, Igor; Zatloukal, Marek; Lenobel, Rene; Hradecka, Dana; Vojtesek, Borivoj; Uldrijan, Stjepan; Mlejnek, Petr; Werbrouck, Stefaan; Strnad, Miroslav
PA Ustav Experimentalni Botaniky Akademie Ved Ceske Republiky, Czech Rep.; et al.
SO PCT Int. Appl., 114 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004058791	A2	20040715	WO 2003-CZ78	20031229
WO 2004058791	A3	20041028		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CZ 294538	B6	20050112	CZ 2002-4273	20021230
AU 2003294608	A1	20040722	AU 2003-294608	20031229
EP 1575973	A2	20050921	EP 2003-785482	20031229
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
ZA 2005006074	A	20060531	ZA 2005-6074	20050728
US 20060166925	A1	20060727	US 2005-540993	20050815
PRAI CZ 2002-4273	A	20021230		
WO 2003-CZ78	W	20031229		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 141:123865
GI



AB The invention concerns novel substitution derivs. of N6-benzyl-adenosine I, wherein n is 2-6; R1 is H, OH, halogen, alkoxy, amino, hydrazo, mercapto, methylmercapto, carboxyl, cyano, nitro, amido, sulfo, sulfamido, acylamino, acyloxy, alkylamino, dialkylamino, alkylmercapto, carbylalkoxy, cycloalkyl, carbamoyl alkyl; R2 is H, OH, halogen, alkoxy, amino, hydrazo, mercapto, methylmercapto, carboxyl, cyano, nitro, amido, sulfo, sulfamido, acylamino, acyloxy, alkylamino, dialkylamino, alkylmercapto, carbylalkoxy, cycloalkyl, carbamoyl, having anticancer, mitotic, immunosuppressive and anti-senescent properties for plant, animal and human cells. This invention also relates to the methods of preparation of these N6-benzyl-adenosine derivs. and their use as drugs, cosmetic prepns. and growth regulators comprising these derivs. as active compound and use of these derivs. for preparation of pharmaceutical comprns., in biotechnol. processes, in cosmetics and in agriculture. Use of title compds. as mitotic or antimitotic compound, especially for treating cancer, psoriasis, rheumatoid arthritis, lupus, type I diabetes, multiple sclerosis, restenosis, polycystic kidney disease, graft rejection, graft vs. host disease and gout, parasitoses such as those caused by fungi or protists, or Alzheimer's disease, or as anti-neurogenerative drugs, or to suppress immunostimulation or for the treatment of proliferative skin diseases. Thus, 2-amino-6-(2-methoxybenzylamino)purine riboside was prepared as growth regulator, and antitumor agent.

IT 420116-42-3P 722505-15-9P 722505-16-0P
722505-17-1P 722505-18-2P 722505-19-3P
722505-20-6P 722505-21-7P 722505-22-8P
722505-23-9P 722505-24-0P 722505-25-1P
722505-26-2P 722505-27-3P 722505-28-4P
722505-29-5P 722505-30-8P 722506-87-8P
RL: AGR (Agricultural use); BSU (Biological study, unclassified); COS (Cosmetic use); IMF (Industrial manufacture); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N6-benzyladenosine nucleosides as antitumor, mitotic, immunosuppressive prodrugs, cosmetic agents, and growth regulators)

RN 420116-42-3 CAPLUS

CN Adenosine, N-([1,1'-biphenyl]-4-ylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 722505-15-9 CAPLUS
CN Adenosine, N-[(4-hexylphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 722505-16-0 CAPLUS
CN Adenosine, N-[[4-(hexyloxy)phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 722505-17-1 CAPLUS
CN Adenosine, N-[(2-formylphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 722505-18-2 CAPLUS
CN Adenosine, N-[(3-formylphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 722505-19-3 CAPLUS
CN Adenosine, N-[(4-formylphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 722505-20-6 CAPLUS
CN Adenosine, N-[(2-ethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 722505-21-7 CAPLUS
CN Adenosine, N-[(3-ethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 722505-22-8 CAPLUS

CN Adenosine, N-[(4-ethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 722505-23-9 CAPLUS
CN Adenosine, N-[(4-ethylphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 722505-24-0 CAPLUS
CN Adenosine, N-[(4-pentylphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 722505-25-1 CAPLUS
CN Adenosine, N-[[4-(pentyloxy)phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 722505-26-2 CAPLUS
CN Adenosine, N-[(4-phenoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 722505-27-3 CAPLUS
CN Adenosine, N-[(4-propylphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 722505-28-4 CAPLUS
CN Adenosine, N-[(4-propoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 722505-29-5 CAPLUS
CN Adenosine, N-[(4-octylphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 722505-30-8 CAPLUS
CN Adenosine, N-[[4-(octyloxy)phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 722506-87-8 CAPLUS
CN Adenosine, N-[(4-butoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2011 ACS on STN
AN 2003:591196 CAPLUS
DN 139:133790
TI Preparation of 2'-β-modified-6-substituted adenosine analogs and their use as antiviral agents
IN An, Haoyun; Ding, Yili; Shaw, Stephanie; Hong, Zhi
PA Ribapharm Inc., USA
SO PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DI Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003062256	A1	20030731	WO 2002-US34026	20021023
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 20060183706	A1	20060817	US 2005-530627	20050407
	US 7217815	B2	20070515		
PRAI	US 2002-350296P	P	20020117		
	WO 2002-US34026	W	20021023		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 139:133790
GI



I

AB Various 2'-beta-methyl-6-substituted adenosine analogs I in which Z is selected from the group consisting of an alkyl, an O-alkyl, an alkenyl, an alkynyl, and CN, wherein the alkyl, the alkenyl, or the alkynyl is optionally substituted with a halogen or OH; A is CH or N, and E is C-R6 or N, such that (1) when A is CH then E is C-R6 or N, and (2) when A is N then E is CH; X is NR1R2, NR2NR3R4, NR2N=NR3, NR2N=CHR3, NR2N=O, NR2C(=O)NR3R4, NR2C(=S)NR3R4, NR2C(=NH)NR3R4, NR1C(=O)NR2NR3R4, NR2OR3, ONHC(O)O-alkyl, ONHC(O)O-aryl, ONR3R4, SNR1R2, SONR1R2, or S(O)2NR1R2; wherein R1-R4 are independently H, alkyl, substituted alkyl, O-alkyl, cyclic alkyl, heterocyclic alkyl, alkoxy, alkaryl, aryl, heterocyclic aryl, substituted aryl, acyl, substituted acyl, S(O)2-alkyl, NO, NH2, or OH; and R6 is H, NH2, halogen, N3, NHR1, NHCOR1 NR1R2, NHSO2R1, NHCONHR1, NHCSNHR1, CH2NHR1, CHR1NHR2, NHNH2, CN, alkyl, alkenyl, alkynyl, CH2-aryl, CH2-heterocycle, halogen, OH, or SH; are prepared by conventional and combinatorial library approaches. Contemplated compds. are particularly useful as therapeutic agents, and especially as antiviral agents. Thus, N6-[3-(methylthio)phenyl]-9H-(2'-β-C-methyl-β-D-ribofuranosyl)adenine was prepared and tested in vitro as antiviral agent against influenza virus A, bovine viral diarrhea virus, Hepatitis B virus, HIV-1 virus and human Rhinovirus.

IT 565435-06-5P

RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)

(preparation of 2'-β-modified-6-substituted adenosine analogs and their use as antiviral agents)

RN 565435-06-5 CAPLUS

CN Adenosine, N-[(2-ethoxyphenyl)methyl]-2'-C-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2011 ACS on STN

AN 2002:89069 CAPLUS

DN 136:355407

TI Anti-Malarial activity of N6-Substituted adenosine derivatives. Part I

AU Golisade, Abolfasl; Wiesner, Jochen; Herforth, Claudia; Jomaa, Hassan; Link, Andreas

CS Institut fur Pharmazie, Universitat Hamburg, Hamburg, D-20146, Germany

SO Bioorganic & Medicinal Chemistry (2002), 10(3), 769-777
CODEN: BMECEP; ISSN: 0968-0896

PB Elsevier Science Ltd.

DT Journal

LA English

OS CASREACT 136:355407

AB The synthesis and biol. evaluation of novel N6-substituted adenosine derivs. is reported. The first series of compds. was obtained using an established procedure for the nucleophilic substitution of a 1-(6-chloro-purin-9-yl)-β-D-1-deoxy-ribofuranose with various amines. In addition, attachment of two different amino-functionalized spacer arms at

the N6-position of adenosine enabled derivatization by an innovative polymer-assisted protocol. Thus, we were able to prepare three series of substituted derivs. that displayed activity vs. the multiresistant Plasmodium falciparum strain Dd2 in cell culture expts.

IT 420116-62-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of and antimalarial structure activity relationship of N6-Substituted adenosine derivs.)

RN 420116-62-3 CAPLUS

CN Adenosine, N-([1,1'-biphenyl]-4-ylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



OSC.G 22 THERE ARE 22 CAPLUS RECORDS THAT CITE THIS RECORD (22 CITINGS)

RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2011 ACS on STN

AN 1996:337912 CAPLUS

DN 125:11378

OREF 125:2497a,2500a

TI Preparation of adenosine derivatives for treating cardiovascular, respiratory, central nervous system, and immune diseases

IN Mitsuya, Morihiro; Takeshita, Hiroshi; Ihara, Masaki

PA Banyu Pharmaceutical Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 12 pp.
CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 08053491	A	19960227	JP 1995-98038	19950330
PRAI JP 1995-98038	A	19950330		
JP 1994-87958	A	19940401		
JP 1994-147104		19940606		

OS MARPAT 125:11378

GI



I

AB The title compds. (I; Ar = Ph, heterocyclyl; Q = lower alkylene; R1 = HOCH2, H2NCO, lower alkylcarbamoyl; R2 = H, HO, NH2, lower alkoxy), which are particularly useful as antihypertensives without side effects such as changing number of heart beats (no data), are prepared Thus, 90 mg 6-amino-3-biphenylylmethylamine dihydrochloride was dissolved in 10 mL EtOH, treated with 0.30 mL Et3N and 82 mg 6-chloro-9-β-D-ribofuranosyl-9H-purine, and refluxed for 8.5 h to give 67% N6-(6-amino-3-biphenylylmethyl)adenosine.

IT 177270-12-1P 177270-16-5P 177270-17-6P
177270-19-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of adenosine derivs. for treating cardiovascular, respiratory, central nervous system, and immune diseases)

RN 177270-12-1 CAPLUS

CN Adenosine, N-[(4-amino[1,1'-biphenyl]-3-yl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 177270-16-5 CAPLUS

CN Adenosine, N-[(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 177270-17-6 CAPLUS
CN Adenosine, N-[[2-amino-5-(1,3-benzodioxol-5-yl)phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 177270-19-8 CAPLUS
CN Adenosine, N-([1,1'-biphenyl]-3-ylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)